LianBio, which is developing in-licensed therapies for a variety of indications in China, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
LianBio is focused on the in-licensing, development, and commercialization of therapeutics in Greater China, including Mainland China, Hong Kong, Taiwan, Macau, and other Asian markets. The company currently has nine programs across five therapeutic areas, including oncology, cardiovascular, and inflammatory diseases. LianBio has in-licensed programs from Bristol Myers Squibb, BridgeBio, and Pfizer, in which LianBio typically buys the rights to pursue the program within China, in exchange for royalties.
The Princeton, NJ-based company was founded in 2019 and plans to list on the Nasdaq under the symbol LIAN. Goldman Sachs, Jefferies, and BofA Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.